Orlando Clinical Research Center

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease6 trials
• Hepatitis B2 trials
• Lung cancer1 trial
• Obesity1 trial

Phase

• Phase 112 trials

Status

• Completed9 trials
• Recruiting3 trials

Lead sponsor

• Incyte Corporation3 trials
• Aligos Therapeutics2 trials
• Amgen2 trials
• Bristol-Myers Squibb2 trials
• Basilea Pharmaceutica1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

  NCT07916181· Phase 1· Basilea Pharmaceutica· Source

  Contact: Thomas Kaindl, MD

• Recruiting

  A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

  NCT07559396· Phase 1· Incyte Corporation· Source

• Recruiting

  A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

  NCT07559474· Phase 1· Incyte Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting

Closed trials

• Completed

  Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

  NCT07342881· Phase 1· Aligos Therapeutics· Source

• Completed

  Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

  NCT07342868· Phase 1· Aligos Therapeutics· Source

• Completed

  A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

  NCT07165015· Phase 1· Eli Lilly and Company· Source

• Completed

  A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

  NCT07429045· Phase 1· Amgen· Source

• Completed

  A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

  NCT06723535· Phase 1· Bristol-Myers Squibb· Source

• Completed

  A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

  NCT06468826· Phase 1· Amgen· Source

• Completed

  A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

  NCT06352528· Phase 1· Bristol-Myers Squibb· Source

• Completed

  Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

  NCT05624723· Phase 1· Incyte Corporation· Source

• Completed

  A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

  NCT05329623· Phase 1· Novartis Pharmaceuticals· Source